Scholarlink

<p>Vasomotor symptoms (VMS—primarily hot flashes and night sweats) are among the most common side effects of endocrine therapy in breast cancer and occur in approximately 30–95% of patients. They significantly impair quality of life as well as adherence to endocrine treatment. A&#xa0;qualitative literature search was conducted on the diagnosis and management of VMS. While the most effective diagnostic approach is the use of patient-reported symptom diaries, several quantitative assessment tools are available, particularly in clinical studies, such as the Hot Flash Score, the Hot Flash-Related Daily Interference Scale (HFRDIS), and the Menopause-Specific Quality of Life (MENQOL) questionnaire. Therapeutic options include complementary approaches such as acupuncture, cognitive behavioral therapy, and hypnotherapy, as well as various pharmacological treatments. In addition to agents long used off-label (such as venlafaxine, gabapentin, and clonidine), new neurokinin receptor antagonists have become available, including fezolinetant and elinzanetant, the latter recently approved in the European Union for use in patients with breast cancer. Raising awareness of VMS and their associated burden, along with knowledge of the full range of therapeutic strategies, is essential for providing optimal care to affected patients and is therefore the aim of this article.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Behandlung vasomotorischer Symptome bei Patientinnen mit Brustkrebs

  • 期刊论文

  • 发表日期：

    2026年4月1日

查看全文
  • Henning Schäffler,
  • Wolfgang Janni,
  • Kerstin Pfister

摘要

Vasomotor symptoms (VMS—primarily hot flashes and night sweats) are among the most common side effects of endocrine therapy in breast cancer and occur in approximately 30–95% of patients. They significantly impair quality of life as well as adherence to endocrine treatment. A qualitative literature search was conducted on the diagnosis and management of VMS. While the most effective diagnostic approach is the use of patient-reported symptom diaries, several quantitative assessment tools are available, particularly in clinical studies, such as the Hot Flash Score, the Hot Flash-Related Daily Interference Scale (HFRDIS), and the Menopause-Specific Quality of Life (MENQOL) questionnaire. Therapeutic options include complementary approaches such as acupuncture, cognitive behavioral therapy, and hypnotherapy, as well as various pharmacological treatments. In addition to agents long used off-label (such as venlafaxine, gabapentin, and clonidine), new neurokinin receptor antagonists have become available, including fezolinetant and elinzanetant, the latter recently approved in the European Union for use in patients with breast cancer. Raising awareness of VMS and their associated burden, along with knowledge of the full range of therapeutic strategies, is essential for providing optimal care to affected patients and is therefore the aim of this article.